Open AccessA new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
Author(s) -
Sara H Bares,
Kimberly K Scarsi
Publication year - 2021
Publication title -
current opinion in hiv and aids
Language(s) - English
Resource type - Journals
eISSN - 1746-6318
pISSN - 1746-630X
DOI - 10.1097/coh.0000000000000708
Subject(s) - rilpivirine , emtricitabine , medicine , dolutegravir , clinical trial , tenofovir , pre exposure prophylaxis , human immunodeficiency virus (hiv) , antiretroviral therapy , pharmacology , viral load , virology , syphilis , men who have sex with men
Cabotegravir (CAB) and rilpivirine (RPV) is the first long-acting injectable antiretroviral therapy (ART) option approved for virologically suppressed adults with HIV-1. In addition, long-acting CAB is a promising agent for HIV preexposure prophylaxis (PrEP). This review focuses on phase 3 clinical trial results and implementation considerations for these long-acting ART and PrEP strategies.